Poster 101
'Surveillance of rotavirus in a rural diarrhoea treatment centre in Bangladesh, 2000–2006'
K. Zaman et al. (IDCDDR, Dhaka, Bangladesh)

Poster 102
'Rotavirus strain types circulating in Africa: Review of studies published 1997–2006'
S Todd, NA Page, AD Steele, I Peenze, NA Cunliffe
(University of Liverpool)

Poster 103
'Pentavalent rotavirus vaccine effectiveness and declines in rotavirus disease burden in the United States'
Daniel C. Payne et al. (CDC, Atlanta, Georgia, USA)

Poster 104
'Molecular diversity of the eleven genome segments of rotavirus genotype G2 strains circulating in the Philadelphia area during a single rotavirus season (2005–2006)'
Max Ciarlet et al.
(Merck Research Laboratories, West Point, Pennsylvania, USA)

Poster 105
'Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, between doses; Potential benefits of early protection'
Max Ciarlet et al.
(Merck Research Laboratories, West Point, Pennsylvania, USA)

Poster 106
'Efficacy of RotaTeq® against rotavirus gastroenteritis-associated healthcare resource utilization for up to 3.1 years postvaccination in Finland'
Max Ciarlet et al.
(Merck Research Laboratories, West Point, Pennsylvania, USA)

Poster 107
'Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, against hospitalizations and emergency department visits up to three years of follow-up: the Finnish Extension Study'
Max Ciarlet et al.
(Merck Research Laboratories, West Point, Pennsylvania, USA)

Poster 108
'GLP evaluation of five live, attenuated oral Shigella dysenteriae 1 vaccine candidates in rhesus monkeys (Macaca mulatta) in an intragastric challenge'
Dilaram Islam et al.
(Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand)

Poster 109
'Structure–function study of Saf and Sef fimbrial polyadhesins reveals a novel strategy for the design of vaccines against salmonella'
Anton V. Zavialov et al.
(Swedish University of Agricultural sciences, Uppsala, Sweden)

Poster 110
'An extraintestinal pathogenic E. coli (ExPEC) vaccine candidate that could potentially protect against a broad spectrum of E. coli pathotypes'
Maria Rita Fontana et al. (Research Center Novartis RöD, Siena, Italy)

Poster 111
'Human herpesvirus 6 (HHV–6) in association with enteric viruses in intestinal intussusceptions (IS): A possible contributing factor to IS caused by viral infections (or vaccine)'
S. Lappalainen et al. (University of Tampere, Finland)

Poster 112
'Genetic analysis of G9 strains isolated in Omaha, Nebraska USA from 1997 to 2000'
S. Mijatovic et al. (CDC, Atlanta, Georgia, USA)

Poster 113
'The chronic effects of acute enteric infections in US military personnel'
Chad K. Porter et al.
(Naval Medical Research Center, Silver Spring, Maryland, USA)

Poster 114
'Co–expression of unnatural combinations of different ETEC colonization factors in high and immunogenic levels'
Joshua Tobias et al. (University of Gothenburg, Sweden)

Poster 115
'Expression of chimeric and immunogenic form of ETEC colonization factors CFA/I and CS2'
Joshua Tobias et al. (University of Gothenburg, Sweden)

Poster 116
'Characterization of immune responses to capsular polysaccharide following Campylobacter jejuni infection in humans'
Shahida Baqar et al.
(Naval Medical Research Center, Silver Spring, Maryland, USA)

Poster 117
'Expression of rotavirus capsid proteins in various host systems for the production of a South African type specific VLP vaccine'
J.J. Smith et al. (Stellenbosch University, South Africa)

Poster 118
'Discrepancy in Campylobacter animal models'
T.A. Luijkkx et al. (Nobilon, Schering–Plough, Boxmeer, The Netherlands)

Poster 119
'Disease and economic burden of rotavirus diarrhea in India'
Jacqueline E. Tate et al. (CDC, Atlanta, Georgia, USA)

Poster 120
'Effectiveness of rotavirus vaccines for the prevention of rotavirus gastroenteritis associated with hospitalization in Israel: a case-control'
Khitam Muhsen et al. (Tel Aviv University, Tel Aviv, Israel)

Poster 121
'Incidence, dynamics and correlates of Helicobacter pylori infection from infancy to school age among Israeli Arab children'
Khitam Muhsen et al. (Tel Aviv University, Tel Aviv, Israel)

Poster 122
'The burden of rotavirus disease in South India'
Gagandeep Kang et al. (Christian Medical College, Vellore, India)

Poster 123
J.P.G. Leite et al.
(Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil)

Poster 124
'Rotavirus sentinel surveillance in Kazakhstan'
E. Flem et al. (Norwegian Institute of Public Health, Oslo, Norway)

Poster 125
'Incidence and epidemiology of childhood intussusceptions in Uzbekistan: a five–year review'
E. Flem et al. (Norwegian Institute of Public Health, Oslo, Norway)
Conference Program – Poster Session

Poster 126
‘Genomic characterization of human rotavirus G8 strains from the African Rotavirus Network (ARN): Relationship to animal rotaviruses’
J. Gentsch et al. (CDC, Atlanta, Georgia, USA)

Poster 127
‘Characterization of unusual human group A rotaviruses from the African Rotavirus Surveillance Network: Detection of single and multiple–gene reassortants’
J. Gentsch et al. (CDC, Atlanta, Georgia, USA)

Poster 128
‘Reduction in gastroenteritis in US children and correlation with early rotavirus vaccine uptake from a national medical claims database’
Margaret M. Cortese et al. (CDC, Atlanta, Georgia, USA)

Poster 129
‘A first antigenemia report in patients with acute rotavirus–associated gastroenteritis in South Africa’
A.D. Steele et al. (PATH, Seattle, Washington, USA)

Poster 130
‘Phylogenetic analysis of serotype G2 strains detected in South Africa between 1984 and 2008: genetic drift over 24 years’
A.D. Steele et al. (PATH, Seattle, Washington, USA)

Poster 131
‘Hospital–based burden of rotavirus disease in Madibeng District, South Africa 2003-2008’
A.D. Steele et al. (PATH, Seattle, Washington, USA)

Poster 132
‘RV3 Rotavirus Vaccine – a neonatal rotavirus vaccine for the global community’
J.E. Bines et al. (The University of Melbourne, Royal Children’s Hospital, Melbourne, Australia)

Poster 133
‘Effect of lactalbumin and antirotavirus immunoglobulin expressed in strawberry or potato plants on rotavirus diarrhea in suckling mice or on rotavirus growth in cultured cells’
Akiko Yui et al. (Fujita Health University School of Medicine, Toyoake, Japan)

Poster 134
‘Surveillance of rotavirus gastroenteritis strains in Blantyre, Malawi’
N.A. Cunliffe et al. (University of Liverpool, UK)

Poster 135
‘Influence of polymer degradation on adjuvant effect of Gantrez®AN nanoparticles during oral vaccination with F4’
Katrin Vandamme et al. (Ghent University, Ghent, Belgium)

Poster 136
‘Comparison of norovirus GII–4 capsid virus like particles (VLPs) purification methods’
L. Teravainen et al. (University of Tampere, Tampere, Finland)

Poster 137
‘Impact of rotavirus vaccination on paediatric gastroenteritis admissions in South Australia’
Helen Marshall et al. (University of Adelaide, Adelaide, Australia)

Poster 138
‘Comparison of clinical and immunological outcomes between two Campylobacter jejuni strains following experimental infection in humans’
David Tribble et al. (Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA)

Poster 139
‘Antigen–specific IgA B memory (B ) cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B among volunteers vaccinated with live–attenuated Shigella flexneri 2a vaccine candidates’
J.K. Simon et al. (University of Maryland School of Medicine, Baltimore, Maryland, USA)

Poster 140
‘Enterotoxigenic E. coli colonization factors: A molecular approach to diminish the fraction of phenotypically-negative isolates’
R.A. Nada et al. (Naval Medical Research Unit-3, Cairo, Egypt)

Poster 141
‘Identification of ETEC expressing atypical putative colonization factor antigens genetically related to CS20 in clinical samples obtained from children with diarrhea’
R.A. Nada et al. (Naval Medical Research Unit-3, Cairo, Egypt)

Poster 142
‘Sustained efficacy of the human rotavirus vaccine RIX4414 (Rotarix™ ) up to 3 years of age in Asian infants’
H.H. Han et al. (GlaxoSmithKline Biologicals, Rixensart, Belgium)

Poster 143
‘Aotus nancymae as a model for ETEC CS17 and CS19 infection and immunity’
Glady’s Nunez et al. (US Naval Medical Research Center Detachment, Lima, Peru)

Poster 144
‘Parallel analysis of mucosally derived B– and T–cell responses to an oral typhoid vaccine using simplified methods’
Anna Lundgren et al. (University of Gothenburg, Gothenburg, Sweden)

Poster 145
‘Prevalence and distribution of norovirus, rotavirus, astrovirus and adenovirus in acute gastroenteritis patients at University Malaya Medical Centre, Kuala Lumpur, Malaysia’
M. Kahar-Bador et al. (University of Malaya, Kuala Lumpur, Malaysia)

Poster 146
‘Cross-protection induced by the Ty21a vaccine (Vivotif® ) against paratyphoid A & B fever’
Tobias Erlanger and Christian Herzog (Crucell (Berna Biotech), Berne, Switzerland)
FINAL ORAL & POSTER PROGRAMMES

The 5th International Conference on Vaccines for Enteric Diseases

VED 2009 9-11 SEPTEMBER 2009
THE TORREQUEBRADA HOTEL, BENALMADINA, MALAGA, SPAIN

Scientific Advisory Panel

Conference Chair: Duncan Steele (PATH, Seattle, Washington, USA)
Greg Glenn (Intercell, Maryland, USA) · Timo Vesikari (University of Tampere, Finland)
Philippe J. Sansonetti (Institut Pasteur, France) · Beatrice de Vos (Sanofi Pasteur, Lyon, France)
Carol O. Tacket (University of Maryland, USA) · Mary Estes (Baylor College of Medicine, USA)
Myron M. Levine (University of Maryland, USA) · John D. Clemens (International Vaccine Institute, Korea)
Eszter Nagy (Intercell AG, Vienna, Austria) · Kevin Killeen (Matrivax Corporation, Boston, USA)
Ann-Mari Svennerholm (Göteborg University, Sweden) · Margaret E. Conner (Baylor College of Medicine, USA)
Linda J. Saif (Ohio State University, USA) · Roger I. Glass (Fogarty Center, NIH, Bethesda, USA)
Harry B. Greenberg (Stanford University, USA) · Lennart Svensson (University of Linköping, Sweden)
Claire-Lise Chaignat (WHO, Switzerland) · John D. Clements (Tulane University, USA) · Umesh Parashar (CDC, Atlanta, USA)
Sims Kochi (Harvard Medical School, Boston, USA) · Albert Z. Kapikian (NIAID/NIH, Bethesda, Maryland, USA)

*Image courtesy of Intercell AG
SESSION 1 – OPENING PLENARY SESSION
Moderator: Ann Mari Svennerholm
(Goteborg University, Goteborg, Sweden)
09.00–09.15
Introduction and Welcome
Duncan Steele (PATH, Seattle, USA)

09.15–09.45
'The legacy of diarrhoeal diseases – cognitive and developmental impairment in those left behind'
Richard Guerrant (University of Virginia, Virginia, USA)

09.45–10.15
'Data on severe diarrhoeal disease burden and etiology from the Global Enteric Multi-Center Study (GEMS)'
Karen Kotloff (University of Maryland, Baltimore, Maryland, USA)

10.15–10.45
'Diarrhoeal and Enteric Vaccines: perspective of the Bill & Melinda Gates Foundation'
Jan Agosti (Bill and Melinda Gates Foundation, Seattle, USA)

10.45–11.15
Coffee Break & Poster Set-Up

SESSION 2 – TYPHOID AND OTHER SALMONELLOSSES
Moderator: Olga Popova (Crucell, The Netherlands)
11.15–11.45
'Invasive non-typhoidal infections: Burden and vaccine development strategies'
Mike Levine (University of Maryland, Baltimore, Maryland, USA)

11.45–12.10
'A strategy for accelerated development, introduction and global use of Vi conjugate typhoid vaccine for infants in developing countries'
S.H. Shin, R. Carbis, G.W. Smith, C. Cui, M.O. Favorov, S. Szu and J.D. Clemens (International Vaccine Institute, Seoul, Korea)

12.10–12.35
'A Vi-based typhoid fever protein capsular matrix vaccine (PCMV)'
Kevin Killeen (Matrivax Inc., Boston, Massachusetts, USA)

12.35–13.00
'The novel, single-oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10^11 colony-forming units'

13.00–14.00
Lunch Break & Posters

SESSION 3 – ROTAVIRUS VACCINES IN DEVELOPING COUNTRIES
Moderator: Duncan Steele (PATH, Seattle, USA)
14.00–14.20
'Efficacy and immunogenicity of human rotavirus vaccine RIX4414 in Malawian infants'
N.A. Cunliffe, D. Witte, B. Ngwira, S. Todd, A.D. Steele, P.V. Purcell, and K.M. Neuzil (University of Liverpool, Liverpool, UK)

14.20–14.40
'Efficacy and immunogenicity of the pentavalent vaccine in Africa'
G.E. Armah (Noguchi Memorial Institute for Medical Research, Legon, Ghana)

Special session continued
14.40–15.00
'RotaTeq® efficacy data in developing countries in Asia'
K Zaman, (International Centre for Diarrhoeal Diseases Research, Dhaka, Bangladesh)

15.00–15.20
'Impact of rotavirus immunization in Latin America'
M Patel, U Parashar, and M Cortese (Centres for Disease Control and Prevention, Atlanta, USA)

15.20–15.40
'Alternative vaccine approaches to prevent Rotavirus diarrhoea among children in poor developing countries'
Roger I. Glass, Umesh Parashar, Baoming Jiang and Jon Gentsch (NIH, Bethesda, Maryland & CDC, Atlanta, Georgia, USA)

15.40–16.00
'A global perspective of rotavirus vaccines for children in developing countries'
K Neuzil, (PATH, Seattle, USA)

16.00–16.30
Tea Break & Posters

SESSION 4 – NOROVIRUS EPIDEMIOLOGY AND VACCINE APPROACHES
Moderator: Carol Tacket (University of Maryland, Baltimore, USA)
16.30–16.50
'Norovirus vaccines: Development of a cost-effective bio-manufacturing and delivery system'
Charles Arntzen (Arizona State University, Tempe, Arizona, USA)

16.50–17.10
'Preclinical development of multivalent Norovirus VLP vaccines'
Charles Richardson, Bryan Steadman, Thomas Foubert, Sheri Klas and William Tino (LigoCyte Pharmaceuticals Inc., Bozeman, Montana, USA)

17.10–17.30
'Phase 1 dose-comparison, safety and immunogenicity of intranasal dry powder Norwalk VLP vaccine'
Carol Tacket, Sharon Frey, David I. Bernstein, John J. Treanor, Samar El-Kamary, Marcela Pasetti, Marcelo Sztein, Jennifer Ferreira and Charles Richardson (University of Maryland, Baltimore, Maryland, USA)

17.30–17.50
'Improving incidence estimates of norovirus-associated infectious intestinal disease in England'
Gemma Philips, Clarence Tam, Laura Rodrigues, David Brown, Miren Iturriza-Gomara, Jim Gray and Ben Lopman (Health Protection Agency, London, UK)

17.50–18.10
'Experimental infection of chimpanzees with Norwalk virus as a new approach for evolution of norovirus vaccine candidates'
Karín Bok, Stanislav V. Sosnovtsev, Tanaji Mitra, Eugenio Abente, Denail Boon, Ronald Engle, Claro Yu, Albert Z. Kapikian, Robert H. Purcell and Kim Y. Green (NAID/NIH, Bethesda, Maryland, USA)

18.30–19.30
VED 2009 Welcome Reception & Poster Session
SESSION 5 – ROTAVIRUS & ROTAVIRUS VACCINES
Moderator: Roger Glass
(Fogarty International Centre, NIH, Bethesda, USA)
08.30-09.00
‘Licensure Monitoring of Rotavirus Vaccination in the United States’
U Parashar, P Haber, M Patel, C Panizomo, D Bartlett, J Tate, J Baggs,
D Payne, M Cortese, E Weintraub, H Clayton, A Curms, J Gentsch.
(CDC, Atlanta, USA)
09.00-09.30
‘Rotavirus genotype distribution in Australian children – what has happened during the first 18 months after introduction of
RotaTeq™ and Rotarix™’
C. Kirkwood, K. Boniface, G. Barnes and R. Bishop
(Royal Children’s Hospital, Parkville, Victoria, Australia)
09.30-09.50
‘Post-marketing surveillance for intussusception surveillance in Australia’
Julie Bines et al.
(The University of Melbourne, Royal Children’s Hospital, Melbourne,
Australia)
09.50-10.20
‘Effectiveness of the monovalent G1P[8] human rotavirus vaccine in Recife, Brazil against severe diarrhoea caused by G2P[4]
rotaviruses’
T Nakagomi, M Patel, O Nakagomi, FM Montenegro, EM Cermano,
NB Corriea, LE Cuevas, U Parashar, NA Cunillie, JB Correia.
(Nagasaki University, Nagasaki, Japan)
10.20-10.50
‘Intussusception and Kawasaki disease – are there still clouds in the skies of rotavirus vaccination?’
Timo Vesikari (University of Tampere, Tampere, Finland)
10.50-11.20
Coffee Break & Posters
11.20-11.40
‘The pentavalent rotavirus vaccine, RotaTeq™: from development to licensure and beyond’
Max Ciarlet (Merck Research Laboratories, North Wales, Pennsylvania,
USA)
11.40-12.00
‘Summary of human rotavirus vaccine RotarixTM : Safety and efficacy trials’
Han Htay Htay, P.V. Suryakiran and RIX4414 vaccine study groups
(OSK Biologicals, Rixensart, Belgium)
12.00-12.20
‘Rotavirus stimulates serotonin (5-HT) release from human enterochromaffin cells. A disease mechanism for vomiting’
Lennart Svensson, Claudia Istrate, Marie Hagbom, Vesa Loitto,
Karl-Erik Magnusson, Hakan Ahlman and Ove Lundgren
(University of Linkoping, Linkoping, Sweden)
12.20-14.00
Lunch Break & Posters
14.00-14.30
PLENARY LECTURE:
‘The value of vaccination for the health and wealth of nations’
David Bloom (Harvard University, Boston, USA)

SESSION 6 – SHIGELLA
Moderator: Armelle Phalipon (Institut Pasteur, Paris, France)
14.30-14.50
‘Shigella-ETEC vaccine trial update’
Karen L. Kotloff (University of Maryland, Baltimore, Maryland, USA)
14.50-15.10
‘Live, attenuated Shigella dysenteriae 1 vaccine development’
Eileen M. Barry (University of Maryland, Baltimore, Maryland, USA)
15.10-15.30
‘Cyclic occurrence of epidemics of Shigella sonnei shigellosis in Israel’
D. Cohen, R. Bassal, L. Valinski, V. Vasilev and M.S. Green
(Tel Aviv University, Tel Aviv, Israel)
15.30-15.50
‘Oral live, attenuated Typhoid-Shigella multivalent vaccine development’
D.J. Kopecko, DeQi Xu, M. Osorio, J. Cisar, V. Truong and E. Patzer
(FDA-CBER, Bethesda, Maryland, USA)
15.50-16.10
‘Safety, colonization, and immunogenicity of second generation live
attenuated virG(icsA)-based Shigella vaccine strains following
nasogastric inoculation of Rhesus Macaques’
Ryan T. Ranallo, Monica Dutta, Robert W. kaminski, Tara L. Boren,
James E. Lee, Monica Buc, Todd Collins, Luis A. Lugo-Roman,
Theron Gilliland Jr., Erica Jones, Shahida Baqar, Shoshana BarNoy,
Akamol E. Suvarnapunya and Malabi M. Venkatesan
(Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)
16.10-16.40
Tea Break & Posters
16.40-17.00
‘A novel approach to produce multivalent glycoconjugated vaccines against Shigelllosis using recombinant bacterial cells that directly
produce immunogenic bioconjugates’
Michael Wacker, Fabiana Fernandez, Michael Wetter, Michael Kowarik,
Cyril Tanner, Stefanie Balada and Gianpietro Corradin
(GlycoVaxyn AG, Schlieren, Switzerland)
17.00-17.20
‘Shigella flexneri 2a Invpalex 50 intranasal vaccine phase 2b challenge study’
C. Harro et al. (Johns Hopkins University, Baltimore, Maryland, USA)

SESSION 7 – ENTERIC BACTERIAL/PARASITIC VACCINES
Moderator: Lou Bourgeois, (PATH, Washington DC)
17.00-17.40
‘Development of a low-dose challenge model for evaluation of vaccines for enterotoxigenic E. coli (ETEC) in volunteers’
Clayton Harro, Barbara DeNeering, Alicia Marcum, Andrea Feller,
Subhra Chakraborty, Barbara Hnzida, August Bourgeois, Richard Walker,
Anna Lundgren , Ann-Mari Svennerholm, and David A. Sack.
(Johns Hopkins School of Public Health, Baltimore, Maryland, USA)
17.40-18.00
‘Characterization of salmonella-specific CD4 T cells to oral infection or vaccination’
Stephen J. McSorley, Amanda Griffin, Seung-Joo Lee and
Joshua McCarr (University of Minnesota Medical School, Minneapolis, Minnesota, USA)
18.00-18.20
‘Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by IFN—γ’
William A. Petri, Xiaoti Guo, Lisa barroso, Steven M. Becker,
William A. Petri, Xiaoti Guo, Lisa barroso, Steven M. Becker,
(University of Virginia, Charlottesville, Virginia, USA)
18.20-18.40
‘Campylobacter jejuni strain CGB421: A new model for the study of human campylobacteriosis’
B.D. Kirkpatrick, D. Tribble, S. Baqar, K. Pierce, M. Carmoli, C. Porter,
M. Darsley (University of Vermont, Burlington, Vermont, USA)
18.40-19.00
‘Capsule-conjugate vaccines against Campylobacter jejuni diarrhea: estimates of required valencies’
Patricia Guerry, Frederic Poly, Oralek Serichantalergs, Piyarat Pootong,
Panida Nobthai, Malla rao, Hind Shaheen, Remon Abu Elyazeed,
John Clemens, Shahida baqar, Eric Hall, Stephen J. Savarino and
Mario A. Monteiro.
(Naval Medical Research Center, Silver Spring, USA)
Free Evening for Delegates
SPECIAL SESSION 8 - MUCOSAL IMMUNIZATION & DELIVERY
Moderator: Jan Holmgren (Goteborg University, Goteborg, Sweden)

08.30-9.00
‘Identification of optimal methods to assess B- and T-cell immune responses against oral enteric vaccines in humans’
Anna Lundgren, Susannah Castenbladh-Leach and Ann-Mari Svennerholm
(Department of Microbiology and Immunology, University of Gothenburg, Sweden)

09.00-09.20
‘Adjuvants that promote mucosal immunity’
John Clements (Tulane University, New Orleans, USA)

09.20-09.40
‘Mucosal immunization against enteric bacterial toxins’
Mingtao Zeng
(University of Rochester School of Medicine, Rochester, New York, USA)

09.40-10.00
‘Transcutaneous delivery of diarrheal vaccines’
Greg Glenn (Intercell Inc., Gaithersburg, Maryland, USA)

10.00-10.20
‘Shigella sonnei human disease model in Thailand’
Ladaporn Bodhidatta, Punnee Pitisuttithum, Supat Chamnachanan, Apichai Srijan, Dilara Islam, Malabi Venkatesan and Carl J Mason
(AFRIMS, Thailand)

10.20-10.40
‘Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera’
Shan Lu, guifang Xu, Shixia Wang, Ling Zhuang, Anthony hacket, Ling Gu, Lu Zhang, Chunhua Zhang, Hua Wang and Zuhu Huang
(University of Massachusetts Medical School, Worcester, Massachusetts, USA)

10.40-11.15 Coffee Break & Posters

SESSION 9 - ENTEROTOXIGENIC E COLI
Moderator: Firdausi Qadri
(International Centre for Diarrhoeal Diseases, Dhaka, Bangladesh)

11.15–11.35
‘Recent epidemiological studies of ETEC in Bangladesh’
F. Qadri (ICDDR, Dhaka, Bangladesh)

11.35–11.55
‘Market Assessment for ETEC vaccines’
D. Atherly, W. Taylor, C Roberts, Malabi Venkatesan and A.L. Bourgeois
(PATH, BCGV, NMRC)

11.55–12.15
‘Construction and expression of fimbrial adhesion–enterotoxin subunit B chimeras as novel enterotoxigenic Escherchia coli (ETEC) vaccine candidates’
Randall K. Holmes, Michael G. Jobling, Stephen J. Savarino, Meredith A. David, Gregory A. Price, Steven T. Poole and Aisling O’Dowd
(University of Colorado Denver School of Medicine, Aurora, Colorado, USA)

12.15–12.35
‘Development of a live attenuated ETEC vaccine for the prevention of diarrhoea in travellers and children in endemic countries’
Michael Darsley (ACE Biosciences, Denmark)

12.35–12.55
‘The use of Gantrez nanoparticles for oral delivery of a vaccine to protect pigs against post-weaning diarrhoea caused by F4+ enterotoxigenic Escherchia coli’
Eric Cox, Vesna Melkebeek, Katrien Vandamme and Jean-Paul Remon
(Ghent University, Merelbeke, Belgium)

12.55–14.00 Lunch Break & Posters

Session 9 continued

14.00–14.20
‘A systematic review of experimental infections with enterotoxigenic Escherchia coli (ETEC)’
Chad Porter
(Naval Medical Research Center, Silver Spring, Maryland, USA)

14.20–14.40
‘A systematic review of ETEC epidemiology focusing on colonization factor (CF) and toxin expression’
Sandra Dakdouk, Mark Riddle and Chad Porter
(Naval Medical Research Center, Silver Spring, Maryland, USA)

SESSION 10 – CHOLERA VACCINES
Moderator: Kevin Killeen
(Matrivax Inc., Boston, USA)

14.40–15.00
‘Killed oral cholera vaccines: Old wine in a new bottle for public health’
John Clemens (International Vaccine Institute, Seoul, Korea)

15.00–15.20
‘Social and cultural features of cholera and vaccine acceptance’
C. Schaetti, S.M. Ali, A.M. Khatib, R.Hutubessy, C.L. Chaignat and M.G. Weiss
(Swiss Tropical Institute, Basel, Switzerland)

15.20–15.40
‘Can oral cholera vaccine play a role in cholera control?’
Claire-Lise Chaignat
(Global Task Force on Cholera Control, WHO, Geneva, Switzerland)

15.40–16.00
LATE BREAKER PRESENTATION:
‘Closed gut-bacteria administration system update’
Marcel Thalen (Synco Bio Partners B.V., The Netherlands)

16.00–16.20 Tea Break & Poster Breakdown

SESSION 11 – CLOSING PLENARY & SUMMARY
Moderator: Duncan Steele (PATH, Seattle, Washington, USA)

16.20–16.50
‘The GAVI portfolio of enteric vaccines – rotavirus, typhoid, cholera’
Jon Pearman (GAVI, USA)

16.50–17.10 Summary and closing remarks
Roger Glass (Fogarty Center, NIH, Bethesda, USA)

17.10 Departure

Please note that this final programme is correct at the time of printing but may be subject to last minute changes.